Open AccessA case of corticosteroid‐refractory adult‐onset Still's disease successfully controlled with tocilizumab despite transient neutropenia and thrombocytopenia
Author(s) -
Iwata Junichi,
Yamamura Hitomi,
Takano Aiko,
Horiuchi Yoshihito
Publication year - 2021
Publication title -
journal of cutaneous immunology and allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.127
H-Index - 1
ISSN - 2574-4593
DOI - 10.1002/cia2.12168
Subject(s) - medicine , tocilizumab , sore throat , neutropenia , prednisolone , corticosteroid , exacerbation , erythema , adverse effect , surgery , disease , chemotherapy
We report a case of a 50‐year‐old woman with adult‐onset Still's disease (AOSD). Even after receiving steroid pulse therapy and high‐dose oral corticosteroid medication, the patient's serum ferritin level increased, while the number of neutrophils and platelets decreased. However, fever, erythema, sore throat, and arthralgia ceased. Therefore, we administered intravenous tocilizumab (TCZ). However, neutropenia, thrombocytopenia, and exacerbation of hyperferritinemia occurred after the first TCZ infusion. After the second TCZ infusion, the values returned to normal, and we discontinued prednisolone successfully without any flare‐ups of AOSD. We reviewed case reports describing adverse events after TCZ administration in AOSD patients.